National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$57.00
add to cart

Rights & Permissions

topleft topright

Priorities for the National Vaccine Plan (2010)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "1 Development of New and Improved Vaccines." Priorities for the National Vaccine Plan. Washington, DC: The National Academies Press, 2010.

Please select a format:

BibTeX EndNote RefMan


Page
50
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Priorities for the National Vaccine Plan

NVAC (National Vaccine Advisory Committee). 1997. United States vaccine research: A delicate fabric of public and private collaboration. Pediatrics 100(6):1015-1020.

NVAC. 2003. Strengthening the Supply of Routinely Recommended Vaccines in the United States. Available: http://www.hhs.gov/nvpo/bulletins/nvac-vsr.htm [accessed August 2009].

NVAC. 2009. National Vaccine Advisory Committee (NVAC) February 5-6, 2009, meeting minutes. In National Vaccine Advisory Committee (NVAC) Meeting. Washington, DC: HHS.

NVPO (National Vaccine Program Office). 2009. Summary Report for Comments on the National Vaccine Plan. Available: http://www.hhs.gov/nvpo/vacc_plan/orise_summary_report.pdf [accessed June 2009].

Oliva, A., R. Levin, R. Behrman, and J. Woodcock. 2007. Bioinformatics modernization and the critical path to improved benefit-risk assessment of drugs. Drug Inf J 42:273-279.

Plotkin, S.A. 2005a. Vaccines: Past, present and future. Nat Med 11(4 Suppl):S5-S11.

Plotkin, S.A. 2005b. Why certain vaccines have been delayed or not developed at all. Health Aff 24(3):631-634.

Plotkin, S.A., W.A. Orenstein, and P.A. Offit. 2008. Vaccines, 5th Edition. Philadelphia: Saunders.

Poland, G.A., R.M. Jacobson, and I.G. Ovsyannikova. 2009. Trends affecting the future of vaccine development and delivery: The role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. Vaccine 27(25-26):3240-3244.

Thalen, M., A. van der Ark, J. van den Ijssel, I. van Straaten, D. Jansen, C. Beuvery, D. Martens, and J. Tramper. 2008. Improving the cellular pertussis vaccine: Increased potency and consistency. Vaccine 26(5):653-663.

Werble, C. 2009a. FDA Sees Boom in Vaccine Applications. Available: http://therpmreport.com/Free/3b15afd4-a05a-4209-bc10-83d5b6c7fa2a.aspx?utm_source=RPMel [accessed May 26, 2009].

Werble, C. 2009b. Vaccine Incentives in the Obama Administration. Available: http://therpmreport.com/Free/2299e06c-0526-4d08-8007-007a9345594d.aspx?utm_source=RPMel [accessed May 26, 2009].

WHO (World Health Organization). 2009. Summary of: WHO Virtual Consultation on the Safety of Adjuvanted Influenza Vaccines. Available: http://www.who.int/vaccine_research/documents/Report_on_consultation_on_adjuvant_safety_2.pdf [accessed November 23, 2009].

Page
50